X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor
Elkins, Jonathan M.
Pattison, Michael J.
Arthur, J. Simon C.
Lizcano, Jose M.
MetadataShow full item record
CitationElkins, Jonathan M., Jing Wang, Xianming Deng, Michael J. Pattison, J. Simon C. Arthur, Tatiana Erazo, Nestor Gomez, Jose M. Lizcano, Nathanael S. Gray, and Stefan Knapp. 2013. “X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor.” Journal of Medicinal Chemistry 56 (11): 4413-4421. doi:10.1021/jm4000837. http://dx.doi.org/10.1021/jm4000837.
AbstractThe protein kinase ERK5 (MAPK7) is an emerging drug target for a variety of indications, in particular for cancer where it plays a key role mediating cell proliferation, survival, epithelial–mesenchymal transition, and angiogenesis. To date, no three-dimensional structure has been published that would allow rational design of inhibitors. To address this, we determined the X-ray crystal structure of the human ERK5 kinase domain in complex with a highly specific benzo[e]pyrimido[5,4-b]diazepine-6(11H)-one inhibitor. The structure reveals that specific residue differences in the ATP-binding site, compared to the related ERKs p38s and JNKs, allow for the development of ERK5-specific inhibitors. The selectivity of previously observed ERK5 inhibitors can also be rationalized using this structure, which provides a template for future development of inhibitors with potential for treatment of disease.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11708540